- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.05. | Virogates A/S Q1 Loss Drops | - | RTTNews | ||
| 07.05. | ViroGates A/S: ViroGates announces its Interim Report for Q1-2026 | 142 | GlobeNewswire (Europe) | Company Announcement no. 5/2026 (May 07, 2026 at 13:12:00 CEST)
Revenue increased 8% Y-o-Y in Q1 to DKK 1.3 million, and net loss decreased by 6% to DKK 2.6 million
BIRKERØD, DENMARK - ViroGates A/S... ► Artikel lesen | |
| 23.04. | ViroGates A/S: Resolutions from the Annual General Meeting of ViroGates A/S | 124 | GlobeNewswire (Europe) | Company Announcement no. 4/2026 (April 23, 2026 at 20:15:00 CEST)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring... ► Artikel lesen | |
| 08.04. | ViroGates A/S: ViroGates submits its De Novo application to the U.S. FDA for suPARnostic TurbiLatex | 291 | GlobeNewswire (Europe) | Company Announcement no. 3/2026 (April 08, 2026 at 22:37:00 CEST)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 26.03. | ViroGates A/S: ViroGates announces its Annual Report 2025: Revenue growth and improved operating result as strategic transition towards preventive health and longevity continues | 710 | GlobeNewswire (Europe) | Company Announcement no. 1/2026 (March 26, 2026 at 15:10:00 CET)
Inside information
BIRKERØD, DENMARK ViroGates A/S ("ViroGates" or "Company"), a medical technology company developing blood tests for... ► Artikel lesen | |
| 12.12.25 | ViroGates A/S: ViroGates announces financial guidance for 2026 | 206 | GlobeNewswire (Europe) | Company Announcement no. 22/2025 (December 12, 2025)
BIRKERØD, DENMARK-ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 28.11.25 | ViroGates A/S: ViroGates' capital raise of DKK 19.3 million and issue of 1,547,412 shares have been registered and settled | 394 | GlobeNewswire (Europe) | Company Announcement no. 21/2025 (November 28, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company") announces that the capital raise of approximately DKK 19.3 million and the issue... ► Artikel lesen | |
| 26.11.25 | ViroGates A/S - increase | 252 | GlobeNewswire | New shares in ViroGates A/S will be admitted to trading on Nasdaq First North Growth Market Denmark as of 28 November 2025. New shares are issued due to a directed issue of new shares.
Name:
ViroGates
ISIN:
DK0061030574
Short... ► Artikel lesen | |
| VIROGATES Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | ViroGates A/S - Observation status | 233 | GlobeNewswire | Nasdaq Copenhagen has today removed observation status for:
ISIN NAME
DK0061030574 VIROGATES
The company's observation status has been removed... ► Artikel lesen | |
| 12.11.25 | ViroGates A/S: suPAR Remedy, LLC announces the outcome of the Public Tender Offer to the shareholders of ViroGates | 243 | GlobeNewswire (Europe) | Company Announcement no. 17/2025 (November 12, 2025)
BIRKERØD, DENMARK - Today, suPAR Remedy, LLC (the "Offeror") announces the outcome of the public tender offer published on 8 October 2025 and on... ► Artikel lesen | |
| 06.11.25 | ViroGates A/S: ViroGates announces its Interim Report for Q1-Q3 2025 | 221 | GlobeNewswire (Europe) | Company Announcement no. 16/2025 (November 06, 2025)
Revenue rose 49% Y-o-Y in Q3, and total revenue for the first nine months is now slightly above the same period in 2024
BIRKERØD, DENMARK - ViroGates... ► Artikel lesen | |
| 08.10.25 | ViroGates A/S - Observation status | 268 | GlobeNewswire | Nasdaq Copenhagen has given the company below observation status:
ISIN DK0061030574 Symbol VIRO
ViroGates A/S has been given observation status, as the company has announced that suPAR... ► Artikel lesen | |
| 08.10.25 | ViroGates A/S: suPAR Remedy, LLC announces public tender offer to the shareholders of ViroGates A/S at a 40% premium | 311 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Company... ► Artikel lesen | |
| 21.08.25 | ViroGates A/S: ViroGates announces its Half-Year Report for H1 2025 | 227 | GlobeNewswire (Europe) | Company Announcement no. 10/2025 (August 21, 2025)
Revenue ending 18% below H1 2024, operating loss reduced by 26%, and proof of concept achieved for suPARnostic® POC+ in longevity
BIRKERØD, DENMARK... ► Artikel lesen | |
| 16.06.25 | ViroGates A/S: ViroGates and GENSPEED achieve proof of concept for their suPARnostic POC+ targeted at the Longevity Testing Market | 309 | GlobeNewswire (Europe) | Company Announcement no. 9/2025 (June 16, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 16,620 | 0,00 % | Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock | ||
| CG ONCOLOGY | 64,25 | -0,53 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| QIAGEN | 30,290 | +0,65 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,240 | -6,38 % | Tango Therapeutics Shares Fall 17% | ||
| PRAXIS PRECISION MEDICINES | 343,26 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,640 | +0,18 % | Cogent Biosciences: Aktie legt vor wichtigen Studiendaten um 4 % zu | ||
| GEOVAX LABS | 3,630 | 0,00 % | EQS-News: GeoVax, Inc.: GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms 20.05.2026 / 16:06... ► Artikel lesen | |
| METAVIA | 3,850 | 0,00 % | MetaVia: Präklinische Studie zu Vanoglipel untermauert Potenzial bei Lebererkrankungen | ||
| IMMUNEERING | 5,390 | +3,26 % | Immuneering Corporation: Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy | - Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,535 | -0,92 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | -0,90 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following... ► Artikel lesen | |
| IMMUNOVANT | 34,140 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,640 | +3,51 % | Beam Therapeutics presents AATD gene therapy trial data at ATS | ||
| INHIBRX BIOSCIENCES | 101,45 | -8,25 % | Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,005 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen |
VIROGATES A/S gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,68 % bei einem Aktienkurs von 1,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIROGATES A/S finden Sie auf Wallstreet Online.